Searchable abstracts of presentations at key conferences in endocrinology

ea0090p368 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

LMF1-associated Chylomicronemia Syndrome

Yacobi Bach Michal , Serebro Merav , Baris Feldman Hagit , Greenman Yona

Introduction: Familial Chylomicronemia-FC syndrome is characterized by severely elevated triglyceride levels, i.e., levels of TG above 1000 mg/dl. Monogenic etiology is associated with a small but a significant fraction of Familial Chylomicronemia (FC) Syndrome cases, which is mainly attributed to a few genes, that are involved in Lipoprotein Lipase activity (LPL / LMF1 / APOC2 / GPIHBP1 / APOA5). Bi-allelic variants in these genes cause this rare Autosomal Recessive ...

ea0070ep124 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

The effect of PCSK9 Inhibitor EVOLOCUMAB on aldosterone among high cardiovascular risk patients

Lzkhakov Elena , Shacham Yakov , Yaron Mariana , Serebro Merav , Tordjman Karen , Greenman Yona , Stern Naftali , Ziv Tomer

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease the degradation of low–density lipoprotein (LDL) receptors, thereby increasing the removal of LDL particles from the blood and significantly reducing LDL cholesterol levels by an average of 65%. Blom et al. showed changes in vitamin E, adrenocorticotropic hormone (ACTH), cortisol, total testosterone, and estradiol in EVOLOCUMAB (PCSK9 inhibitor)–treated patients 1. Ther...